

Ref. No: 0269
Date: 20/09/23
Subject: Treatment of Breast Cancer

REQUEST

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023? *Please provide data for the latest 3-month period, if Jun to Aug is not available yet.*
 - Abemaciclib (Verzenios)
 - Alpelisib (Piqray)
 - Fulvestrant (fulvestrant or Faslodex)
 - Palbociclib (Ibrance)
 - Ribociclib (Kisqali)
2. How many patients received abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of June 2023 and end of August 2023? *Please provide data for the latest 3-month period, if Jun to Aug is not available yet.*
3. How many patients received abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the 3 months between the start of June 2023 and end of August 2023? *Please provide data for the latest 3-month period, if Jun to Aug is not available yet.*
4. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023? *Please provide data for the latest 3-month period, if Jun to Aug is not available yet.*
 - *Curative*
 - *Palliative*
 - *Not known / stated*
5. How many patients were treated with the following medicines in combination in the 3 months between the start of June 2023 and end of August 2023? *Please provide data for the latest 3-month period, if Jun to Aug is not available yet.*
 - Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)

- **Abemaciclib (Verzenio) + an aromatase inhibitor (anastrozole, letrozole or exemestane)**
- **Abemaciclib (Verzenio) + tamoxifen**
- **Abemaciclib monotherapy**
- **Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)**
- **Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)**
- **Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)**
- **Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)**
- **Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)**

RESPONSE

The Trust has not supplied any of the drugs listed in the request.